Monto AS, Gunn RA, Bandyk MG, King CL. 1979. Prevention of Russian influenza by amantadine. JAMA 241:1003–1007.

Monto AS, Robinson DP, Herlocher ML, Hinson JM Jr, Elliott MJ, Crisp A. 1999a. Zanamivir in the prevention of influenza among healthy adults: A randomized controlled trial. JAMA 282:31–35.

Monto AS, Webster A, Keene O. 1999b. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: Pooled efficacy analysis. J Antimicrob Chemother 44(Suppl B):23–29.

Murphy K, Eivindson A, Pauksens K, Stein WJ, Tellier G, Watts R, Leophonte P, Sharp SJ, Loeschel E. 2000. Efficacy and safety of inhaled zanamivir for the treatment of influenza in patients with asthma or chronic obstructive pulmonary disease. Clin Drug Invest 20:337–349.


Nafta I, Turcanu AG, Braun I, Companetz W, Simionescu A, Birt E, Florea V. 1970. Administration of amantadine for the prevention of Hong Kong influenza. Bull WHO 42:423–427.

NIAID (National Institute of Allergy and Infectious Diseases). 2004. NIAID Taps Chiron to Develop Vaccine Against H9N2 Avian Influenza. Award Part of NIAID Pandemic Influenza Preparedness Program. [Online]. Available: http://www2.niaid.nih.gov/newsroom/releases/h9n2.htm [accessed November 10, 2004].

Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M. 2003. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med 348:1322–1332.

Node K, Fujita M, Kitakaze M, Hori M, Liao JK. 2003. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 108:839–843.

Novak K. 2003. The WTO’s balancing act. J Clin Invest 112:1269–1273.


Official Journal of the European Community. 1995. Article 7b, Regulation 541/95. European Union: Publications Office of the European Union.

Official Journal of the European Community. 2003. Article 8, Regulation 1085/2003. European Union: Publications Office of the European Union.

Oker-Blom N, Hovi T, Leinikki P, Palosuo T, Pettersson R, Suni J. 1970. Protection of man from natural infection with influenza A2 Hong Kong virus by amantadine: A controlled field trial. BMJ 3:676–678.


Patriarca PA, Cox NJ. 1997. Influenza pandemic preparedness plan for the United States. J Infect Dis 176(Suppl 1):S4–S7.

Peiris JS, Yu WC, Leung CW, Cheung CY, Ng WF, Nicholls JM, Ng TK, Chan KH, Lai ST, Lim WL, Yuen KY, Guan Y. 2004. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 363:617–619.

Peters PH, Gravenstein S, Norwood P, DeBock V, Van Cauter A, Gibbens M, van Planta T-A, Ward P. 2001. Long term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatric Soc 49:1–7.

Pettersson RF, Hellstrom PE, Penttinen K, Pyhala R, Tokola O, Vartio T, Visakorpi R. 1980. Evaluation of amantadine in the prophylaxis of influenza A (H1N1) virus infection: A controlled field trial among young adults and high-risk patients. J Infect Dis 142:377–383.

Plotkin E, Bernheim J, Ben-Chetrit S, Mor A, Korzets Z. 2000. Influenza vaccine—a possible trigger of rhabdomyolysis induced acute renal failure due to the combined use of cerivastatin and bezafibrate. Nephrol Dial Transplant 15:740–741.


Quarles JM, Couch RB, Cate TR, Goswick CB. 1981. Comparison of amantadine and rimantadine for prevention of type A (Russian) influenza. Antiviral Res 1:149–155.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement